2023年7月6日

汽车公司的纳米黏土RENOVITE载体可用于放置一些制药药物和生物制剂治疗。Biocomposites的投资有助于基金上市前通过RENOVITE作为骨科的载体,脊椎和外伤的应用程序。信贷:这里最好的健身/ Shutterstock.com。医疗器械公司Biocomposites已经获得了英国汽车公司的少数股权生物制剂,一笔资金。汽车公司开发了一种合成,生物可降解的纳米黏土载体称为RENOVITE。推荐报告承运人打算一些药物和生物制剂在治疗。23-gauge插管是利用注射这个载体来支持的微创手术。它将转变成一个僵硬的凝胶后就接触生理液体如血清。cell-responsive载体,它加速愈合较低剂量的治疗药物。雷诺生物制剂首席执行官阿格涅斯卡Janeczek博士说:“我们一直认为RENOVITE克服挑战的潜力在组织再生提供了前所未有的保留治疗现场修复。“汽车公司将获得进入Biocomposites的专业技能和知识在药物载体发展,推进贸易和投资自由化便利化RENOVITE上市前通过载体骨科,脊椎和外伤的应用程序。 Furthermore, Biocomposites CEO Michael Harris will join the board of directors of Renovos. Harris said: “The potential for RENOVITE as a next-generation drug carrier that can enhance the activity of therapeutic drugs at lower doses, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting. “Following on from our recent acquisition of Artoss in June this year and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.” Last month, Biocomposites acquired German bone graft substitutes manufacturer Artoss. The company offers NanoBone technology, which can be used as a synthetic degradable bone graft substitute. Share this article